Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: The MIRACEL study

Current Medical Research and Opinion

Volumn 26, Issue 5, 2010, Pages 1083-1089

  Fliser, D ^a   Kleophas, W ^b   Dellana, F ^b   Winkler, R E ^c   Backs, W ^d   Kraatz, U ^e   Fassbinder, W ^f   Wizemann, V ^e   Strack, G ^e  

^a SAARLAND UNIVERSITY   (Germany)

^b Dialysezentrum   (Germany)

^c Universittsklinikum Rostock   (Germany)

^d Dialysepraxis Barmbeck   (Germany)

^e KfH Nierenzentrum ^*  (Germany)

^f KfH Nierenzentrum   (Germany)

Author keywords

Continuous erythropoietin receptor activator (C.E.R.A.); Conversion; Erythropoiesis stimulating agents; Haemodialysis; Haemoglobin levels

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ANGINA PECTORIS; AORTA VALVE STENOSIS; ARTICLE; BACKACHE; BRAIN ISCHEMIA; BRONCHITIS; CLINICAL DECISION MAKING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COUGHING; DECUBITUS; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLU LIKE SYNDROME; GASTROENTERITIS; GERMANY; HEADACHE; HEART ATRIUM FIBRILLATION; HEART DEATH; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; INTESTINE INFARCTION; IRON THERAPY; LARGE INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; RHINOPHARYNGITIS; SCREENING TEST; SEPSIS; SIDE EFFECT; SYRINGE; TACHYCARDIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING;

EPOETIN ALFA; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; RENAL DIALYSIS;

EID: 77951030186     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003666652     Document Type: Article

References (28)

1. Thorp ML, Johnson ES, Yang X, et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton) 2008 [epub ahead of print]
2. Kovesday CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006;69:560-564 (Pubitemid 43164450)
3. Li S, Foley RN, Collins AJ. Anemia, hospitalisation, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004;65:1864-1869
4. Levin A, Djurdjev O, Duncan J, et al. Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes. Nephrol Dial Transplant 2006;21:370-377
5. Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:33-38
6. Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005;45:658-666
7. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94-111
8. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530
9. Locatelli F, Covic A, Eckardt K-U, et al. on behalf of the ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009;24:348-354
10. Valderrá bano F, Hörl WH, Macdougall IC, et al. PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 2004;18:89-100
11. Lacson Jr E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Kidney Int 2003;41:111-124
12. Ebben JP, Gilbertson DT, Roley RN, et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-1210
13. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-1343
14. Yang W, Israni RK, Brunelli SM, et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007;18:3164-3170
15. Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 2002;17 (Suppl 1): 53-59
16. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin beta. Clin Pharmacol Ther 1991;50:702-712
17. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoi-esis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10: 2392-2395
18. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharma-codynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-1215
19. de Francisco AL, Sulowicz W, Klinger M, et al.; BA16260 Study Investigators. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract 2006;60:1687-1696
20. Provenzano R, Besarab A, Macdougall IC, et al.; BA 16528 Study Investigators. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol 2007;67:306-317
21. Macdougall IC, Walker R, Provenzano R, et al.; ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008; 3:337-347
22. Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007;50:989-1000
23. Canaud B, Mingardi G, Bruno J, et al.; STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008;23:3654-3661
24. Locatelli F, Villa G, De Francisco ALM, et al.; BA16286 Study Investigators. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis. Curr Med Res Opin 2007; 23:969-979
25. Levin NW, Fishbane S, Cañ edo FV, et al.; MAXIMA Study Investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370:1415-1421
26. Sulowicz W, Locatelli F, Ryckelynck JP, et al.; PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2: 637-646
27. Spinowitz B, Coyne DW, Lok CE, et al.; RUBRA Study Investigators.C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrology 2008;28:280-289
28. Institute of Medicine Committee on Identifying and Preventing Medication Errors, Board on Health Care Services. Preventing medication errors. http://www.nap.edu/catalog/11623.html (accessed April 15, 2009)